Ambu A/S

Ambu A/S

AMBFF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$3.3B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Ambu A/SAmbu A/S37.90.45%10%0.50.1

Earnings Call Q4 2026

November 5, 2026 - AI Summary

Good - Strong H2 endoscopy re-acceleration, A&PM remains the drag: Q4 organic revenue grew 13.9% (16% reported including positive USD/DKK FX), with Endoscopy Solutions +21.2% and Anesthesia & Patient Monitoring (A&PM) +2.8%, taking full-year organic growth to 10.1% within guidance. For the full year Endoscopy grew 16.4% - Respiratory +14.6% (Q4 +21%, H2 +19% driven by aScope 4/5 and SureSight) and Urology/ENT/GI +18.2% (Q4 +21.3%) - now almost 2/3 of sales, while A&PM grew only 0.4% for the year (Patient Monitoring +6.5% in Q4 offset by anesthesia volume losses in non-exclusive US accounts first flagged after Q2, now stabilised but with only gradual recovery expected and 3-5% long-term growth assumed thereafter).
Surprising / Bad - Q4 EBIT margin flattered by one-off tariff refund, gross margin flat: Full-year gross margin was flat at 60.1% (Q4 60%) despite favourable endoscopy mix, as accelerated production shift Malaysia-to-Mexico raised COGS to manage tariffs/agility - partly offset by lower distribution costs in OpEx, described as EBIT-neutral. OpEx ratio improved only 0.2pp to 47% for the year (Q4 42.8%), and EBIT margin rose to 13.2% from 13.0% last year, but Q4's 17.2% included a DKK 85m tariff refund worth ~5pp of margin, minus ~DKK 20m (~1pp) of Q4 tariff costs and TIMS transaction/integration costs in Q3-Q4, so underlying leverage is more modest than the headline Q4 jump suggests.
Forecast FY2026/27 - Second year below midterm growth range, investment-heavy year: Management guided organic growth of 9.5%-11.5%, Endoscopy ~15% (Respiratory moderating around the +14.6% achieved this year, Urology/ENT/GI strong but slightly below +18.2%, A&PM low single-digit and H2-weighted on tough Q1 comparables), EBIT margin 13%-15% with an assumed -1pp tariff drag and *no* tariff refunds included (up to DKK 70m potential identified, targeting at least half), and cash conversion of only ~30% versus 39% this year due to higher CapEx for manufacturing capacity, R&D and launch preparation for the next endoscope generations. This implies growth and margin acceleration must be back-ended.

Exclusive for Stockcircle Pro members

Sign upSign Up
$10.38

Current Fair Value

17.4% downside

Overvalued by 17.4% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$3.30 Billion
Enterprise Value$3.39 Billion
Annual dividend$0.06
Dividend yield0.45%
Earnings per Share$2.44
Beta1.34
Outstanding Shares262,765,957

Return

Return on Equity10.27%ROE
Return on Assets7.81%
Return on Invested Capital12.42%

Valuation & Multiples

P/E Ratio37.87P/E Ratio
PEG32.99PEG
Price to Sales0.52Price to Sales
Price to Book Ratio0.55Price to Book Ratio
Enterprise Value to Revenue0.52
Enterprise Value to EBIT3.96
Enterprise Value to Net Income5
Total Debt to Enterprise0.18
Debt to Equity0.1Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 5, 2026
EPS
$0.14
Est. $0.13
Revenue
$257.04 M
Est. $252.55 M

Next Earnings Call

Expected Date
January 28, 2027
EPS Estimate
$0.11
Consensus analyst estimate
Revenue Estimate
$261.98 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Ambu A/S

5,384 employees
CEO: Britt Meelby Jensen

Ambu A/S engages in the development, production, and marketing of diagnostic and life-supporting devices for hospitals and rescue services. It operates through the following segments: Anaesthesia; Patient Monitoring & Diagnostics; and Vi...

Questions & Answers